FDA Advisory Committee Recommends Specialty Pharmacy Access for Two Peptides, Diverging from FDA Staff Concerns

Miami Fort Lauderdale, FL, July 23, 2026 —

An advisory committee to the U.S. Food and Drug Administration (FDA) has voted to recommend that two peptides, identified as BP-157 and KPV, be added to a list that would permit their distribution through specialty pharmacies. This recommendation signifies a divergence from the concerns previously raised by FDA staff regarding these substances.

FDA staff had advised against the recommendation, citing a perceived lack of sufficient scientific evidence and potential safety concerns associated with BP-157 and KPV. Despite these reservations from the agency’s own staff, the advisory committee proceeded with its vote in favor of allowing specialty pharmacy access.

It is important to note that the advisory committee’s vote is not a final decision. The process will now move to a public rulemaking stage, which will involve further deliberation and public input before any official policy changes are enacted. This step is a standard part of the FDA’s regulatory procedures.

The move by the advisory committee to recommend specialty pharmacy dispensing for these peptides is considered unusual because it appears to bypass the conventional, evidence-based drug approval pathway typically overseen by the FDA. Standard drug approval involves rigorous clinical trials and extensive data review to establish efficacy and safety.

The specific details regarding the evidence presented to the committee, the exact nature of the safety concerns, and the implications of dispensing these peptides through specialty pharmacies, rather than via the standard FDA approval route, were not elaborated upon in the provided summary. The outcome of the public rulemaking process remains to be seen.

Story summarized from the original created by Alana Semuels on time.com, see more information here.

Media gallery